Clinical trials: Streptococcus Pneumoniae Infections
Complement Deficiency, Antibody Deficiency
Systematic Search for Primary Immunodeficiency in Adults With Infections
Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections …
- Conditions
- Complement Deficiency, Antibody Deficiency, Chronic Sinus Infection, Meningitis, Bacterial
- Trial name
- SPIDAC (NCT02972281)
- Testing
- Immunological diagnosis tests
- Where
- 19 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Lille
Pneumococcal Infections, Pneumonia, Pneumococcal
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals.
- Trial name
- NCT02116998
- Testing
- GEN-004 with Aluminum Hydroxide Adjuvant, Streptococcus pneumoniae inoculation
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Genocea Biosciences, Inc.
Pneumonia, Respiratory Tract Diseases
Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine
Infections with Streptococcus pneumoniae often cause serious health problems, especially for infants and the elderly.Failure to cover all polysaccharide types is an even greater problem with adults than with children.
- Conditions
- Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- PⅠCTPV (NCT04087460)
- Testing
- Protein based pneumococcal vaccine(Low dose), Protein based pneumococcal vaccine(Middle dose), Protein based pneumococcal vaccine(High dose)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Pneumococcal Infections, Streptococcal Infections
Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT04841369
- Testing
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 3,420 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
HIV Infections
Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.
Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3.
- Trial name
- NCT00148824
- Testing
- 7-valent pneumococcal conjugate vaccine (vaccine), 23-valent pneumococcal conjugate vaccine (vaccine)
- Where
- France
- Volunteers
- 212 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Streptococcus Pneumoniae Pneumonia
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07035054
- Testing
- low dose-1, low dose-2, high dose
- Where
- China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in children aged 2 Months (Minimum 6 Weeks) to 17 Years .
- Trial name
- NCT06675032
- Testing
- PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Infections, Streptococcal
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali
The purpose of this trial is to assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A when administered either as a booster dose or as a two dose catch-up vaccination…
- Trial name
- NCT00985465
- Testing
- Pneumococcal vaccine GSK1024850A
- Where
- Mali
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Meningococcal
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
The purpose of this study is to compare the immediate and long term (up to 5 years) immunogenicity and safety of GSK Biologicals' MenACWY-TT vaccine when given as a single dose or as 2 doses to toddlers aged 12 to 14 months.
- Trial name
- NCT01939158
- Testing
- Meningococcal vaccine GSK134612, Prevenar 13™
- Where
- 51 sites in Australia, Canada and 4 more
- Volunteers
- 803 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Phase I Study of XJ103 in Chinese Healthy Subjects
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria.
- Trial name
- NCT06026748
- Testing
- XJ103 Injection
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Starmab biologics（Shanghai）Co,.ltd
Pneumococcal Disease
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age.
- Trial name
- NCT05464420
- Testing
- V116, PPSV23
- Where
- 72 sites in United States, Austria and 6 more
- Volunteers
- 2,162 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Streptococcal
Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
The purpose of this observer blind study is to assess the safety in terms of fever >39°C (rectal temperature) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK…
- Trial name
- NCT00547248
- Testing
- Synflorix, Tritanrix-HepB, Hiberix
- Where
- 7 sites in Philippines, Poland
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants
This study will assess the safety, reactogenicity and immunogenicity of two formulations of GSK Biologicals' pneumococcal vaccine 2189242A given as a 3-dose primary vaccination course during the first 6 months of life followed by…
- Trial name
- NCT01204658
- Testing
- Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix
- Where
- 24 sites in Czechia, Germany and 2 more
- Volunteers
- 576 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
The purpose of this study is to evaluate the safety and immunogenicity of sequential administration of Prevnar 13™ and Pneumovax™ 23 in healthy participants 50 years of age and older.
- Trial name
- NCT02225587
- Testing
- Prevnar 13™, Pneumovax™ 23
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not previously been immunized with Pneumococcal…
- Trial name
- NCT00452452
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 9 sites in Poland
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Meningococcal Meningitis, Measles
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers.
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00422292
- Testing
- Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,664 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Streptococcus Pneumoniae Pneumonia, Streptococcus Pneumoniae Infection
Pneumococcal Nasopharyngeal Colonization as Predictor of Community-Acquired Pneumonia (CAP) in Adults With Chronic Diseases.
Streptococcus pneumoniae (pneumococcus) is a commensal bacterium, often isolated in the nasopharynx of preschool children and older adults with weakened immune systems, a pathogen that remains the leading cause of…
- Conditions
- Streptococcus Pneumoniae Pneumonia, Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae Infection Invasive, Community-acquired Pneumonia
- Trial name
- CAP (NCT04944719)
- Testing
- nasopharyngeal aspirate
- Where
- Colombia
- Volunteers
- 810 people
- Sponsor
- Universidad de la Sabana
Infections, Streptococcal
A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study
Evaluate lot-to-lot consistency, safety and reactogenicity of 3 doses of GSK Biologicals' 10-valent pneumococcal conjugate vaccine and non-inferiority with respect to Prevenar.
- Trial name
- NCT00307554
- Testing
- Pneumococcal (vaccine)
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Study Evaluating Prevenar Vaccine in Healthy Infants
To determine the immunogenicity of Prevenar in infants immunized at 2, 4 and 6 months of age. To determine the antibody responses to the seven pneumococcal vaccine serotypes one month after second dose and determine the safety of…
- Trial name
- NCT00276107
- Testing
- Prevenar
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer